Paul Haluska, Jr, MD, PhD | Authors

The Pathway Ahead in Melanoma Trials

May 13, 2009

Reviewing treatment modalities for melanoma provides many sobering reminders that advances in our scientific understanding have not yet translated into meaningful clinical benefit. As clearly delineated by the authors, the “standard” treatment of dacarbazine chemotherapy has a poor response rate and lacks durability.